Between the simplicity of in vitro models (monoculture, co-culture) and the complexity of a clinical study, reconstructed 3D models and ex vivo tissue occupy a strategic position in substantiating a skin microbiome claim. They make it possible to observe a host-microbe interaction in an environment structurally close to real skin, without the ethical constraints and inter-individual variability inherent to human volunteers. Here is what each of these models offers, and for which type of claim they are relevant.
Reconstructed 3D models: observing the tissue response to microbial colonization
3D reconstructed skin models, comprising full-thickness epidermis and dermis layers, provide a physiologically relevant testing platform for analyzing host-microbe interactions. By inoculating these models with commensal or pathogenic strains, laboratories can simultaneously monitor tissue response, skin barrier integrity, inflammatory signaling, and microbial colonization.
These models are particularly valuable for evaluating cosmetic formulations under controlled, reproducible conditions, while minimizing the variability associated with human volunteers. They also allow for the assessment of product safety, irritation potential, and the efficacy of a topical treatment aimed at restoring microbial balance, before moving on to a clinical study.
Ex vivo models: a compromise between tissue fidelity and ethical feasibility
Ex vivo studies use freshly excised human skin or scalp tissue to evaluate microbial interactions within their native structural and biochemical environment. Unlike a reconstructed 3D model, these tissues retain the natural lipid composition, barrier properties, and resident microbial populations, offering a closer approximation of in vivo conditions.
Cosmetic ingredients can be applied topically to evaluate their impact on microbial diversity, metabolic activity, and barrier integrity. These approaches are particularly useful for evaluating formulations targeting sensitive or specific populations, such as infants or patients with dermatological conditions, for whom ethical constraints limit, or exclude, the use of standard in vivo studies.
How these two models complement each other in a study protocol
The table below summarizes the respective uses of 3D and ex vivo models, to be integrated into a broader evidence strategy ahead of the clinical study.
| Criterion | 3D reconstructed model | Ex vivo model |
|---|---|---|
| Tissue origin | Laboratory-reconstructed skin | Freshly excised skin or scalp |
| What it documents | Tissue response to microbial colonization, safety, irritation | Microbiome behavior in its native structural environment |
| Populations concerned | Standard, controlled conditions | Sensitive populations (infants, pathological skin) where in vivo is limited |
| Reproducibility | High, variability minimized | More variable, depends on tissue donor |
| Main limitation | Does not reproduce full native microbial diversity | Limited tissue viability window |
| Position in the protocol | Safety and efficacy screening before clinical | Validation in a real tissue context, an alternative to in vivo for sensitive populations |
Positioning these models correctly in your study brief
For a claim related to restoring microbial balance, the 3D model documents the mechanism of action at the tissue level (inflammation, barrier), while the ex vivo model confirms that this effect holds up in a native microbial environment, with its own residual diversity. Combined, these two levels of evidence significantly strengthen the credibility of a claim file ahead of the clinical study, particularly for brands developing products for populations where in vivo experimentation remains ethically constrained.
To identify laboratories offering 3D or ex vivo models suited to your microbiome claim, the Skinobs platform references specialized providers.
Discover skin microbiome testing solutions on Skinobs → https://www.skinobs.com/
